| Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. (NCT04712721) | Novartis Pharmaceuticals | 2021-10-14 |
| Asciminib Treatment Optimization in ≥ 3rd Line CML-CP (NCT04948333) | Novartis Pharmaceuticals | 2021-10-13 |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP (NCT04971226) | Novartis Pharmaceuticals | 2021-10-06 |
| Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) (NCT04930094) | Novartis Pharmaceuticals | 2021-10-06 |
| Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NCT04926818) | Novartis Pharmaceuticals | 2021-10-05 |
| Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma (NCT05714371) | Novartis Pharmaceuticals | 2021-10-02 |
| Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib (NCT05675683) | Novartis Pharmaceuticals | 2021-10-01 |
| Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 (NCT04935359) | Novartis Pharmaceuticals | 2021-09-30 |
| Study of Diagnostic Performance of [18F]CTT1057 in BCR (NCT04838613) | Novartis Pharmaceuticals | 2021-09-30 |
| Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan (NCT05974397) | Novartis Pharmaceuticals | 2021-09-30 |
| A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China (NCT04894890) | Novartis Pharmaceuticals | 2021-09-26 |
| Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD (NCT04882124) | Novartis Pharmaceuticals | 2021-09-24 |
| Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (NCT04816214) | Novartis Pharmaceuticals | 2021-09-22 |
| Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) (NCT04868968) | Novartis Pharmaceuticals | 2021-09-20 |
| Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis (NCT04886258) | Novartis Pharmaceuticals | 2021-09-20 |
| A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy (NCT04557462) | Novartis Pharmaceuticals | 2021-09-20 |
| Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. (NCT04623216) | Novartis Pharmaceuticals | 2021-09-14 |
| Risk Perception in Multiple Sclerosis (NCT05528666) | Novartis Pharmaceuticals | 2021-09-09 |
| Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (NCT04851873) | Novartis Pharmaceuticals | 2021-09-08 |
| Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma (NCT04946318) | Novartis Pharmaceuticals | 2021-09-08 |
| Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection (NCT04838626) | Novartis Pharmaceuticals | 2021-09-07 |
| A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer (NCT05067140) | Novartis Pharmaceuticals | 2021-09-02 |
| Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®) (NCT05816720) | Novartis Pharmaceuticals | 2021-09-01 |
| Characteristics of Patients With Sickle Cell Disease (NCT05494541) | Novartis Pharmaceuticals | 2021-08-30 |
| A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (NCT04814368) | Novartis Pharmaceuticals | 2021-08-27 |
| Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion (NCT05657158) | Novartis Pharmaceuticals | 2021-08-23 |
| Regulatory Post-Marketing Surveillance Study for Brolucizumab (NCT04985487) | Novartis Pharmaceuticals | 2021-08-18 |
| Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment (NCT06666114) | Novartis Pharmaceuticals | 2021-08-03 |
| Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data (NCT06392763) | Novartis Pharmaceuticals | 2021-08-03 |
| Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure (NCT05613140) | Novartis Pharmaceuticals | 2021-08-02 |
| Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients (NCT05806268) | Novartis Pharmaceuticals | 2021-07-30 |
| Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers (NCT05833022) | Novartis Pharmaceuticals | 2021-07-30 |
| A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (NCT04939610) | Novartis Pharmaceuticals | 2021-07-30 |
| Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (NCT04817618) | Novartis Pharmaceuticals | 2021-07-28 |
| Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT04747613) | Novartis Pharmaceuticals | 2021-07-27 |
| A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia (NCT04943497) | Novartis Pharmaceuticals | 2021-07-27 |
| Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (NCT04788615) | Novartis Pharmaceuticals | 2021-07-23 |
| A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil (NCT06715254) | Novartis Pharmaceuticals | 2021-07-23 |
| Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected (NCT04729387) | Novartis Pharmaceuticals | 2021-07-22 |
| Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis (NCT04732117) | Novartis Pharmaceuticals | 2021-07-21 |
| Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056 (NCT04771143) | Novartis Pharmaceuticals | 2021-07-21 |
| Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent (NCT04722666) | Novartis Pharmaceuticals | 2021-07-20 |
| Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy (NCT04820530) | Novartis Pharmaceuticals | 2021-07-19 |
| Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study (NCT06991894) | Novartis Pharmaceuticals | 2021-07-14 |
| An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients (NCT04662931) | Novartis Pharmaceuticals | 2021-07-14 |
| Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration (NCT04679935) | Novartis Pharmaceuticals | 2021-07-13 |
| Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support (NCT04807400) | Novartis Pharmaceuticals | 2021-07-07 |
| A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia. (NCT04806503) | Novartis Pharmaceuticals | 2021-06-30 |
| Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia (NCT04784390) | Novartis Pharmaceuticals | 2021-06-30 |
| Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (NCT04940065) | Novartis Pharmaceuticals | 2021-06-30 |
| A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE) (NCT04929249) | Novartis Pharmaceuticals | 2021-06-25 |
| Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo. (NCT04711902) | Novartis Pharmaceuticals | 2021-06-24 |
| Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome (NCT04873934) | Novartis Pharmaceuticals | 2021-06-24 |
| VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) (NCT04702425) | Novartis Pharmaceuticals | 2021-06-23 |
| Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS (NCT04810611) | Novartis Pharmaceuticals | 2021-06-18 |
| 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (NCT04689828) | Novartis Pharmaceuticals | 2021-06-15 |
| Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study (NCT04657822) | Novartis Pharmaceuticals | 2021-06-10 |
| A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab (NCT04878211) | Novartis Pharmaceuticals | 2021-06-10 |
| Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice (NCT06737419) | Novartis Pharmaceuticals | 2021-06-09 |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (NCT04720157) | Novartis Pharmaceuticals | 2021-06-09 |
| Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma (NCT04589663) | Novartis Pharmaceuticals | 2021-06-07 |
| Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study (NCT05677542) | Novartis Pharmaceuticals | 2021-06-02 |
| A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (NCT04812548) | Novartis Pharmaceuticals | 2021-05-31 |
| Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis (NCT04864392) | Novartis Pharmaceuticals | 2021-05-31 |
| Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab (NCT04869358) | Novartis Pharmaceuticals | 2021-05-27 |
| Open-label Extension Study for CLCZ696G2301 (PARADISE-MI) (NCT04637555) | Novartis Pharmaceuticals | 2021-05-26 |
| Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (NCT04666259) | Novartis Pharmaceuticals | 2021-05-25 |
| Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence (NCT04797000) | Novartis Pharmaceuticals | 2021-05-25 |
| A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab (NCT04847596) | Novartis Pharmaceuticals | 2021-05-21 |
| Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (NCT04677595) | Novartis Pharmaceuticals | 2021-05-17 |
| Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants (NCT04896632) | Novartis Pharmaceuticals | 2021-05-13 |
| Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis (NCT04676555) | Novartis Pharmaceuticals | 2021-05-11 |
| Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal (NCT04764656) | Novartis Pharmaceuticals | 2021-05-10 |
| A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 (NCT04828161) | Novartis Pharmaceuticals | 2021-05-10 |
| French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients (NCT05619978) | Novartis Pharmaceuticals | 2021-05-03 |
| Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma (NCT05874817) | Novartis Pharmaceuticals | 2021-05-01 |
| Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia (NCT05893836) | Novartis Pharmaceuticals | 2021-04-27 |
| Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP) (NCT04630158) | Novartis Pharmaceuticals | 2021-04-21 |
| A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis. (NCT04836858) | Novartis Pharmaceuticals | 2021-04-20 |
| Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (NCT04589650) | Novartis Pharmaceuticals | 2021-04-19 |
| Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) (NCT04792567) | Novartis Pharmaceuticals | 2021-04-19 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (NCT04603495) | Novartis Pharmaceuticals | 2021-04-09 |
| A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT07103486) | Novartis Pharmaceuticals | 2021-04-01 |
| Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD (NCT04717635) | Novartis Pharmaceuticals | 2021-03-30 |
| Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer (NCT05569187) | Novartis Pharmaceuticals | 2021-03-23 |
| Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis (NCT05513014) | Novartis Pharmaceuticals | 2021-03-21 |
| Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis (NCT04645589) | Novartis Pharmaceuticals | 2021-03-16 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases (NCT04573920) | Novartis Pharmaceuticals | 2021-03-15 |
| Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs (NCT04727723) | Novartis Pharmaceuticals | 2021-03-09 |
| Study Conducted Among Patients With CML (NCT05476562) | Novartis Pharmaceuticals | 2021-03-08 |
| Special Drug Use Surveillance for Entresto Tablets (NCT04781881) | Novartis Pharmaceuticals | 2021-03-04 |
| Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C) (NCT04765657) | Novartis Pharmaceuticals | 2021-03-01 |
| Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C (NCT04774003) | Novartis Pharmaceuticals | 2021-02-26 |
| Effectiveness and Safety of Omalizumab in Children With Allergic Asthma. (NCT05424523) | Novartis Pharmaceuticals | 2021-02-25 |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (NCT04699188) | Novartis Pharmaceuticals | 2021-02-24 |
| A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (NCT04662944) | Novartis Pharmaceuticals | 2021-02-23 |
| Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients (NCT04667949) | Novartis Pharmaceuticals | 2021-02-20 |
| Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy (NCT04539041) | Novartis Pharmaceuticals | 2021-02-16 |
| Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia (NCT04659863) | Novartis Pharmaceuticals | 2021-02-16 |
| Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria (NCT04546633) | Novartis Pharmaceuticals | 2021-02-16 |